Drug Pipeline

NSCLC Therapy is Increasingly Targeted

December 08, 2021

Drugs in development and newly approved drugs for non-small cell lung cancer are based on research that has identified driver mutations leading to runaway cell growth and division that characterize cancer.

Pipeline for Atopic Dermatitis is Full — and Full of Promise, but…

November 05, 2021

Safety concerns may limit JAK inhibitors as treatment for the common skin condition.

Drugmakers Look to Quell COVID-19 Cytokine Storms

October 06, 2021

The FDA rejected Humanigen’s application for an emergency use authorization, but the race is on to develop an effective therapy for the cytokine storms that affect patients with COVID-19.

Promising Liver Disease Drugs in the Pipeline for 2021 to 2022

September 03, 2021

Three notable medications to treat liver diseases are expected to come online in the third quarter of 2021 and in 2022, according to PBM OptumRx.

Aduhelm OK Engulfed by Controversy

August 13, 2021

Accelerated approval and use of surrogate markers are among the friction points. But some see the OK as spawning a new generation of drug development for treating Alzheimer’s disease.

2021 Starts Off Strong — and Controversial

July 12, 2021

Not in recent memory has an FDA approval stirred up so much controversy as the agency’s OK of Aduhelm, Biogen’s Alzheimer’s treatment.

2021 Managed Healthcare Executive® Pharmacy Survey: Drugs New to the Market Most Likely to Reduce Morbidity, Mortality

June 16, 2021

In this part five series, participants give their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.